A preliminary analysis of the first effective coronavirus vaccine can prevent more than 90 percent of people from contracting the virus.
The is according to the well-known multinational pharmaceutical company, Pfizer and its German partner, BioNTech — the developers of this vaccine.
A November 9 report from the British Broadcasting Corporation (BBC) said Pfizer’s vaccine has been tested on 43,500 people across six countries (US, Germany, Brazil, South Africa, Turkey, and Argentina) and no safety concerns have been raised.
The BBC said the vaccine developers plan to apply for emergency approval to use the vaccine by the end of the month.
The vaccine must be taken in doses two doses at three weeks apart and the results from the trials have shown that 90 percent protection is achieved seven days after the second dose.
The current data is subject to change as further analysis will get underway, the developers have said.
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis,” said Dr Albert Bourla, the chairman of Pfizer.
Once the vaccine is approved by regulators, Pfizer and BioNTech said they will be able to supply 50 million doses by the end of this year and around 1.3 billion by the end of 2021.
According to the BBC, the UK should get 10 million doses by the end of the year, with a further 30 million doses already ordered. The United Kingdom has guaranteed to procure COVID-19 vaccines for the British Virgin Islands and other Overseas Territories.
Copyright 2021 BVI News, Media Expressions Limited. All Rights Reserved. This material may not be published, broadcast, rewritten or distributed.